Pharmacogenomics of Human Diseases
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: closed (25 July 2023) | Viewed by 292
Special Issue Editors
Interests: SNPs; genetic associations; genomics; complex diseases; pharmacogenetics; systematic review
Interests: target drug delivery; drug interaction; nanoparticles; stem cells; micro aesthetics; oral diseases; systematic reviews
Special Issue Information
Dear Colleagues,
Over the last few decades, genomics has emerged in the medical and pharmaceutical fields for understanding the causes of diseases, pathogenesis, diagnosis, genetic susceptibility, drug treatments, and implementation of pharmacogenetic methods for personalized medicines. Understanding the function and structure of the genomic pharmacogenomic technology by finding the various genes involved in metabolic, pathogenic, transporter, and epigenetic regulation of human diseases is greatly needed. Pharmacogenomics helps in finding at-risk patients. To determine the best therapeutic treatment, an individual’s genetic profile in response to the drug is generally studied in large populations and reported from various countries. The genetic variation could attribute the changes in proteins to cellular concentration, metabolic activities, altered stability and signaling properties. Hence, the application of pharmacogenomics could prevent severe drug reactions and might reduce health care costs and efficiency. However, there are a few challenges in the development and practical uses of pharmacogenomics, such as: expensive techniques, limited availability of specific genetic tests in institutes and organizations, and privacy issues.
This Special Issue mainly focuses on “Pharmacogenomics of Human Diseases” and highlights the modern approaches to finding the genetic predisposition in response to drugs treating various human diseases. In addition, this issue could bring up valuable ideas and research findings from the worldwide researchers involved in the multidisciplinary backgrounds in the field of pharmacogenomics and related disciplines.
We are inviting researchers to submit their research findings that have been focused on molecular mechanisms, novel therapies and the identification of genetic variants in response to drugs in terms of original research articles, narrative reviews, systematic reviews and meta-analyses in this Special Issue: “Pharmacogenomics of Human Diseases” in the journal Genes.
Prof. Dr. R. Vasudevan
Prof. Dr. Sindhu Ramesh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genetic variant
- drug interactions
- pharmacogenetic
- non-communicable disease
- single nucleotide polymorphism
- molecular genetics and genomics
- personalized medicine
